Romain Guyon, Ph.D., The Jenner Institute, University of Oxford
University of Oxford Ph.D., The Jenner Institute
“Demonstration of new single-dose vaccine technology towards a first-in-man clinical application.”
Single-dose immunization could provide an effective solution to improving global vaccination coverage and easing the logistical and cost burdens during outbreaks.
Mr. Guyon uses a novel microfluidics system to generate biodegradable particles that can deliver priming and booster vaccines as a single injection.
Mr. Guyon’s successful Michelson Prize proposal will assess the utility of this technology using the licensed rabies vaccine for single-visit post-exposure prophylaxis and assess scale up feasibility to facilitate a first-in-human clinical trial.
About Romain Guyon:
Romain Guyon graduated in Biosciences Engineering at the Institut National des Sciences Appliquées of Lyon (INSA de Lyon), France, in 2018 and obtained an MSc in biomedical engineering.
He was then awarded the NDM Prize Studentship at the University of Oxford, where he is currently finishing his DPhil in Clinical Medicine, based between the Jenner Institute and the Institute of Biomedical Engineering (IBME), before starting a postdoctoral position in these institutes (Jenner and IBME) in the University of Oxford to develop further his work on single-dose vaccine technology.
Romain’s research is focused on developing a new technology for delayed vaccine delivery, using encapsulation by microfluidics to produce single-dose vaccines.
He developed a working platform that has demonstrated suitable delayed release of a vaccine booster dose in vitro and in vivo, using a malaria vaccine candidate as Proof of Concept, which led to a patent application.
With the Michelson Prize, he intends to use his technology to encapsulate the licensed rabies vaccine that would greatly benefit from a conversion to a single-dose regimen, thus improving global coverage, reducing the number of preventable deaths, and easing the logistical and cost burden.